<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831619</url>
  </required_header>
  <id_info>
    <org_study_id>2013/CHU/12</org_study_id>
    <nct_id>NCT04831619</nct_id>
  </id_info>
  <brief_title>Contribution of PET (Positron Emission Tomography) Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN</brief_title>
  <acronym>TEP-ENDORUN</acronym>
  <official_title>Contribution of PET Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometriosis is an inflammatory condition that is often treated by surgery. MRI and&#xD;
      ultrasound are used for the preoperative morphological assessment. Currently, only surgery&#xD;
      allows the exhaustive and qualitative diagnosis of lesions.&#xD;
&#xD;
      The PET scan, fixing in certain inflammatory pathologies and in certain cases of&#xD;
      endometriosis, could refine this assessment by evaluating the location of the lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the PET scan in the diagnosis of endometriosis lesions compared to surgery in terms of number of lesions diagnosed and locations.</measure>
    <time_frame>at inclusion (before surgery)</time_frame>
    <description>Total number of endometriosis lesions diagnosed by the PET scanner</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the results of the PET scanner and MRI for the sensitivity of detection of endometriosis lesions</measure>
    <time_frame>up to 14 weeks (after surgery)</time_frame>
    <description>number of endometriosis lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the results of the PET scanner and MRI for the sensitivity of detection of endometriosis lesions</measure>
    <time_frame>up to 14 weeks (after surgery)</time_frame>
    <description>location of endometriosis lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define a reading threshold of SUV (Standardized Uptake Value) on a PET scanner for the diagnosis of endometriosis</measure>
    <time_frame>up to 14 weeks (after PET-Scanner)</time_frame>
    <description>degree of inflammation of the cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>PET scanner in addition to MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)</intervention_name>
    <description>A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).</description>
    <arm_group_label>PET scanner in addition to MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged over 18 and under 50&#xD;
&#xD;
          -  Patient with symptomatic endometriosis with indication for surgery&#xD;
&#xD;
          -  Showing at least one typical endometriosis lesion on MRI, greater than 5mm&#xD;
&#xD;
          -  Accepting surgical management&#xD;
&#xD;
          -  Having signed an informed consent after information&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has received an injection with GnRH (gonadotropin-releasing hormone )&#xD;
             analogues for less than 3 months (because it induces the quiescence of the disease&#xD;
             which is no longer stimulated by estrogen secretion)&#xD;
&#xD;
          -  Patient with a history of heavy abdominopelvic surgery&#xD;
&#xD;
          -  Diabetic patient&#xD;
&#xD;
          -  Patient unable to understand the interest of the study&#xD;
&#xD;
          -  Patient already included in another therapeutic trial with an experimental molecule.&#xD;
&#xD;
          -  Persons referred to in articles L1121-5 to L1121-8 of the PHC (public health code)&#xD;
             (corresponding to all protected persons: pregnant woman, parturient, nursing mother,&#xD;
             person deprived of liberty by judicial or administrative decision, minor, and person&#xD;
             making the subject to a legal protection measure: guardianship or curators)&#xD;
&#xD;
          -  Contraindications to PET Scanner (major claustrophobia, contraindication or&#xD;
             hypersensitivity to 18-FDG or one of its excipients, contraindication or&#xD;
             hypersensitivity to Ultravist® or one of its excipients, etc.)&#xD;
&#xD;
          -  Contraindication to surgery or anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucie AUZANNEAU</last_name>
    <phone>(0)262 35 99 49</phone>
    <phone_ext>+33</phone_ext>
    <email>lucie.auzanneau@chu-reunion.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucie AUZANNEAU</last_name>
      <phone>(0)262 35 99 49</phone>
      <phone_ext>+33</phone_ext>
      <email>lucie.auzanneau@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Peter VON THEOBALD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Réunion</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucie AUZANNEAU</last_name>
      <phone>(0)262 35 99 49</phone>
      <phone_ext>+33</phone_ext>
      <email>lucie.auzanneau@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Malik BOUKERROU, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

